- NEWS
Controversial COVID study that promoted unproven treatment retracted after four-year saga
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-024-04014-9
References
Gautret, P. et al. Int. J. Antimicrob. Agents 56, 105949 (2020).
Rosendaal, F. R. Int. J. Antimicrob. Agents 56, 106063 (2020).
Brouqui, P. et al. New Microbes New Infect. 55, 101188 (2023).
Axfors, C. et al. Nature Commun. 12, 2349 (2021).
Frank, F. et al. Res. Integr. Peer Rev. 8, 9 (2023).
Barraud, D. et al. Therapies 78, 437–440 (2023).
The COVID pandemic’s lingering impact on clinical trials
Latin America’s embrace of an unproven COVID treatment is hindering drug trials
Long COVID exercise trials proposed by NIH raise alarm
Inhaled COVID vaccines stop infection in its tracks in monkey trials